Semaglutide Research: The GLP-1 Receptor Agonist and What Its Trial Programmes Investigated

What is semaglutide?

What is semaglutide? Chemically, an acylated analogue of human glucagon-like peptide-1 — a 31-residue backbone based on GLP-1(7–37), carrying two deliberate substitutions and a fatty-acid side chain at a single lysine. Its discovery paper (Lau et al., 2015, J Med Chem) describes it as a once-weekly GLP-1 analogue selected from a design campaign aimed at increasing albumin affinity and securing full stability against metabolic degradation.

It is the active molecule in several branded prescription products — a factual identification, offered without benefit framing, with regulatory status covered below. The material described here is a laboratory synthetic supplied as a lyophilized powder for bench work: not the marketed medicine, not equivalent to it, not for human use.

Discovery and origin in the literature

Semaglutide is a deliberate second-generation redesign of an earlier molecule. Knudsen and Lau (2019, Frontiers in Endocrinology, PMID 31031702) set out that lineage directly — a single review covering the discovery and development of both liraglutide and semaglutide, written by two of the chemists involved. Liraglutide had established that acylating a GLP-1 analogue produced reversible albumin binding and a once-daily profile; the semaglutide programme asked what would have to change to reach a once-weekly one.

Lau et al. (2015) answer in the abstract itself: the fatty-acid moiety and the linking chemistry were the key features to secure high albumin affinity and GLP-1 receptor potency while obtaining prolonged exposure. Semaglutide was selected as the optimal once-weekly candidate, and that paper is the source for the design and receptor-affinity descriptions here.

Reference data and molecule design

Drawn from the discovery literature and the public chemical record (PubChem CID 56843331). Any field that could not be sourced is omitted rather than estimated.

Mechanism — a single-receptor agonist

The semaglutide mechanism described in the discovery pharmacology is agonism at exactly one receptor — the architectural point of the molecule, and what makes it the baseline the multi-agonists are engineered against:

• GLP-1 receptor (GLP-1R) — the incretin receptor targeted by native GLP-1. Semaglutide engages this receptor and no other by design: no GIP arm, no glucagon arm. Lau et al. measured its affinity at 0.38 ± 0.06 nM, roughly three-fold lower than liraglutide, with albumin affinity increased in exchange.
• Albumin-mediated persistence — the C18 diacid at Lys26, joined through a hydrophilic spacer, acts on no receptor at all. It binds albumin, a pharmacokinetic mechanism rather than a signalling one, converting a peptide with a native half-life of minutes into one measured at 46.1 hours in mini-pigs.
• Protease resistance — the Aib8 substitution replaces the alanine that dipeptidyl peptidase-4 (DPP-4) cleaves in native GLP-1, so the molecule survives the step that inactivates the endogenous hormone. The same trick is later reused at two positions in tirzepatide.

Because it is the single-agonist reference case, semaglutide appears constantly as the comparator in other molecules’ work — tirzepatide’s SURPASS-2, survodutide’s open-label comparator arm, preclinical benchmarking for mazdutide. The cross-class side-by-side of receptor targets lives on the comparison page, which this page deliberately does not restate.

What the SUSTAIN, STEP, PIONEER and SELECT programmes investigated

Semaglutide carries the largest clinical literature of any compound in this catalogue, in four named programmes. Each entry records what the study examined and in whom — not results:

SUSTAIN (subcutaneous, type 2 diabetes)

• Sorli et al., 2017 (Lancet Diabetes Endocrinol, PMID 28110911) — SUSTAIN 1, a phase 3a double-blind placebo-controlled monotherapy trial in people with type 2 diabetes; the anchor of the programme.
• Marso et al., 2016 (NEJM, PMID 27633186) — SUSTAIN-6, which investigated cardiovascular outcomes in people with type 2 diabetes at elevated cardiovascular risk.

STEP (subcutaneous, obesity)

• Wilding et al., 2021 (NEJM, PMID 33567185) — STEP 1, a phase 3 trial in adults with overweight or obesity. STEP is the obesity counterpart to SUSTAIN.

PIONEER (oral formulation)

• Husain et al., 2019 (NEJM, PMID 31185157) — PIONEER 6, a cardiovascular-safety trial of the oral formulation in people with type 2 diabetes.
• Overgaard et al., 2021 (Clin Pharmacokinet, PMID 33969456) — a pooled analysis characterising the pharmacokinetics of oral semaglutide, co-formulated with the absorption enhancer SNAC.

SELECT (cardiovascular, obesity without diabetes)

• Lincoff et al., 2023 (NEJM, PMID 37952131) — SELECT, which investigated cardiovascular outcomes in adults with overweight or obesity and established cardiovascular disease but without diabetes. Cited because it defines a population the earlier programmes did not study — a fact about trial design, not a claim about results.

None of these is presented with outcome figures. The purpose here is to record what the trials investigated and who ran them.

Research models, evidence status, and what is not established

Semaglutide is an unusual case in a research-peptide catalogue: the human evidence base is large and well controlled, the opposite of the situation for most compounds in the research library. What is established is the molecule’s structure and synthesis route, its GLP-1R affinity and albumin binding as measured in vitro, its long half-life as measured in animals and characterised in human pharmacokinetic analyses, and the existence of large randomised trials in defined patient populations run by the manufacturer and reported in the journals cited below. Semaglutide is also an approved prescription medicine in many jurisdictions, in both subcutaneous and oral formulations — stated as a matter of public record.

What is not established, and is deliberately not claimed here: anything at all about the research material supplied to a laboratory. Those trial results were generated with a manufactured, regulated pharmaceutical product administered under medical supervision in a monitored population; they say nothing about a research-grade powder and are not transferable to any other setting. An approval likewise attaches to that regulated product supplied through a pharmacy against a prescription, not to a reagent. Compare survodutide and cagrilintide, both still investigational, and mazdutide, whose approval is jurisdiction-specific. Nothing here is medical, efficacy, dosing or use guidance of any kind, and the material is not for human or veterinary use.

How to verify this compound yourself

For a 31-residue acylated peptide, identity and purity are established by two orthogonal analytical methods, both reported on a per-batch Certificate of Analysis:

• HPLC purity — reversed-phase chromatography separates the target peptide from related impurities and reports purity as a percentage of the chromatogram. For acylated analogues this is the method that reveals a des-acyl species, which differs from the target only by the missing side chain.
• Mass-spec identity — mass spectrometry confirms the measured mass against the expected molecular weight (≈ 4114 Da). The C18 diacid and its spacer contribute several hundred daltons, so a missing side chain is visible as a mass shift rather than hidden inside the peptide envelope.
• Endotoxin / sterility — where tested, separate quality attributes reported independently of chemical purity.

See how to read a COA for what each certificate line means, how to verify peptide purity for how the two methods fit together, and how to spot a fake COA. Check the exact batch on the self-serve verify tool.

Research-grade sourcing and verification

Semaglutide is not held in Cellworks stock. It appears in the sourcing catalogue as available to order: our supplier lists it, we have not bought it, and sourcing takes roughly two to three weeks. No price is quoted until availability is confirmed, and there is no cart button, because implying we hold material we do not hold is the one thing a verification-led catalogue cannot do.

Anything sourced this way is a laboratory research reagent with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spectrometry identity. Nothing here is an offer of a medicine.

Frequently asked questions

Literature cited

1. Lau J, Bloch P, Schäffer L, et al. “Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.” J Med Chem. 2015;58(18):7370–7380. PMID 26308095. pubmed.ncbi.nlm.nih.gov/26308095.
2. Knudsen LB, Lau J. “The Discovery and Development of Liraglutide and Semaglutide.” Front Endocrinol (Lausanne). 2019;10:155. PMID 31031702. pubmed.ncbi.nlm.nih.gov/31031702.
3. Sorli C, Harashima SI, Tsoukas GM, et al. “Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1).” Lancet Diabetes Endocrinol. 2017;5(4):251–260. PMID 28110911. pubmed.ncbi.nlm.nih.gov/28110911.
4. Marso SP, Bain SC, Consoli A, et al. “Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” (SUSTAIN-6) N Engl J Med. 2016;375(19):1834–1844. PMID 27633186. pubmed.ncbi.nlm.nih.gov/27633186.
5. Wilding JPH, Batterham RL, Calanna S, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” (STEP 1) N Engl J Med. 2021;384(11):989–1002. PMID 33567185. pubmed.ncbi.nlm.nih.gov/33567185.
6. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” (SELECT) N Engl J Med. 2023;389(24):2221–2232. PMID 37952131. pubmed.ncbi.nlm.nih.gov/37952131.
7. Husain M, Birkenfeld AL, Donsmark M, et al. “Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.” (PIONEER 6) N Engl J Med. 2019;381(9):841–851. PMID 31185157. pubmed.ncbi.nlm.nih.gov/31185157.
8. Overgaard RV, Navarria A, Ingwersen SH, et al. “Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials.” Clin Pharmacokinet. 2021;60(10):1335–1348. PMID 33969456. pubmed.ncbi.nlm.nih.gov/33969456.
9. National Center for Biotechnology Information. “PubChem Compound Summary for CID 56843331, Semaglutide.” pubchem.ncbi.nlm.nih.gov/compound/56843331 (formula, mass, CAS 910463-68-2).